Bladder Cancer

Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.

A decision is expected by the fourth quarter of 2026.

Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in patients with MIBC with complete response to neoadjuvant therapy.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.

Datopotamab deruxtecan will be assessed alone and in combination with rilvegostomig as adjuvant treatment for patients with high-risk muscle-invasive urothelial carcinoma.

The NDA submission is supported by data from the phase 3 UTOPIA trial.

Nima Almassi, MD, reviews long-term evidence for bladder preservation after systemic therapy in muscle-invasive bladder cancer.

A claims-based analysis found blue light cystoscopy was associated with increased health care resource use in NMIBC without significantly increasing total costs.

The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Recent data suggest that bladder cancer burden is increasing across age groups, with a disproportionate rise among younger women.

Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.

Phase 3 BOND-003 data published in Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.

Experts discuss why accurately recognizing CIS in patients with suspected NMIBC is essential to preventing disease progression, guiding surveillance, and expanding treatment and clinical trial opportunities.

Can Aydogdu, MD, highlights a study examining the utility of pre-surgical tumor-informed ctDNA to predict pathologic nodal status at radical cystectomy.

The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.

Experts discuss practical strategies to improve the detection of CIS through closer urologist-pathologist collaboration, optimized biopsy techniques, and complementary diagnostic tools.

Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.

Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.